In this issue of Nature Metabolism, Mi and colleagues provide evidence that super-enhancers play a critical role in autosomal-dominant polycystic kidney disease (ADPKD) and show that CDK7 targeting provides a novel therapeutic option.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sengupta, S. & George, R. E. Trends Cancer 3, 269–281 (2017).
Bergmann, C. et al. Nat. Rev. Dis. Primers 4, 50 (2018).
Shillingford, J. M., Piontek, K. B., Germino, G. G. & Weimbs, T. J. Am. Soc. Nephrol. 21, 489–497 (2010).
Takiar, V. et al. Proc. Natl Acad. Sci. USA 108, 2462–2467 (2011).
Rowe, I. et al. Nat. Med. 19, 488–493 (2013).
Podrini, C. et al. Commun Biol 1, 194 (2018).
Padovano, V., Podrini, C., Boletta, A. & Caplan, M. J. Nat. Rev. Nephrol. 14, 678–687 (2018).
Menezes, L. F., Lin, C. C., Zhou, F. & Germino, G. G. EBioMedicine 5, 183–192 (2016).
Seeger-Nukpezah, T., Geynisman, D. M., Nikonova, A. S., Benzing, T. & Golemis, E. A. Nat. Rev. Nephrol. 11, 515–534 (2015).
Mi, Z. et al. Nat. Metab. https://doi.org/10.1038/s42255-020-0227-4 (2020).
Pema, M. et al. Nat. Commun. 7, 10786 (2016).
Acknowledgements
The authors are grateful to A. Mondino and D. Gabellini for critically reading the manuscript. A.B. and L.C. are supported by the Italian Ministry of Health, the PKD Foundation and the Italian Association for Research on Cancer (AIRC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.B. is a co-inventor on two patents for the targeting of cell metabolism in ADPKD.
Rights and permissions
About this article
Cite this article
Cassina, L., Boletta, A. Metabolic reprogramming in polycystic kidney disease explained by super-enhancers and CDK7: new therapeutic targets?. Nat Metab 2, 659–660 (2020). https://doi.org/10.1038/s42255-020-0232-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-020-0232-7